Navigation Links
Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
Date:10/13/2008

New Analysis of SPIRIT II and SPIRIT III Data Confirms Patients Treated with XIENCE V Are at Lower Risk of Experiencing Death, a Heart Attack or a

Repeat Procedure Compared to TAXUS(R) at Two Years

WASHINGTON, Oct. 13 /PRNewswire-FirstCall/ -- Data from an independent meta-analysis of Abbott's SPIRIT II and SPIRIT III randomized clinical trials demonstrated that the XIENCE V(TM) Everolimus Eluting Coronary Stent System continues to deliver clinically significant benefits for patients compared to the TAXUS(R) paclitaxel-eluting coronary stent system out to two years. In this meta-analysis, which included patients from the United States, Europe and Asia-Pacific, XIENCE V demonstrated clinical superiority to TAXUS in the endpoints of target vessel failure (TVF) and major adverse cardiac events (MACE) at two years. XIENCE V also demonstrated significantly lower clinical events rates than TAXUS in the key efficacy (target lesion revascularization) and safety (cardiac death or heart attack) components of MACE at two years. The results are being presented by Gregg W. Stone, M.D., principal investigator of the SPIRIT III trial, during the Cardiovascular Research Foundation's 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

"The pooled results from the SPIRIT II and SPIRIT III trials demonstrate that XIENCE V is safer and provides greater efficacy than TAXUS at two years," said Dr. Stone, professor of medicine at Columbia University Medical Center and chairman, Cardiovascular Research Foundation, New York. "In the meta-analysis at two years, XIENCE V compared to TAXUS demonstrated statistically significant reductions in the combined measure of all-cause death or heart attack, as well as further reducing the need for repeat cardiac procedures -- reinforcing that XIENCE V is a true second-generation stent, which results in improved patient outcomes."

The meta-analysis of 1,302 patients from the SPIRIT I
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
2. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
3. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
4. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
5. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
6. Dynavaxs HEPLISAV(TM) Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial
7. Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System
8. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
9. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
10. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
11. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... NEW YORK , March 27, 2015 ... in Santa Ana, California is a ... market for which is estimated at $22 billion in the ... includes the use of FDA-approved Naltrexone in a specially compounded ... (excluding Australia and New ...
(Date:3/27/2015)... MISSISSAUGA, ON , March 27, 2015 /CNW/ - ... an advanced medical technologies company, today announced the issuance ... independent directors of the Company and an aggregate of ... Company. The stock options will vest over three years ... years at an exercise price of $1.40 per stock ...
(Date:3/27/2015)... March 27, 2015 /PRNewswire/ - Medicure Inc. (the "Company") ... has approved the grant of an aggregate of 236,070 ... and consultants of the Company pursuant to the Company,s ... to expire on the tenth anniversary of the date ... third anniversary of the date of grant and 50,000 ...
Breaking Medicine Technology:Small Cap IR Correction -- BioCorRx Inc. Positions Itself Through Strategic Partnerships To Gain Market Share Of The $22 Billion Substance Abuse Treatment Market In The U.S. 2Covalon Announces Issuance of Stock Options 2
(Date:3/28/2015)... Tucson, AZ (PRWEB) March 28, 2015 Coffee ... could also help protect you from gum disease, researchers have ... protected against gum disease. , Coffee contains antioxidants. Antioxidants fight ... is the question researchers at Boston Univ. Henry M. Goldman ... published in the August 2014 issue of the Journal of ...
(Date:3/28/2015)... March 28, 2015 Take a bite ... kicks into action. Acids tumble into the stomach, ready ... faulty valve-like structure lets these acids run amok, triggering ... extremely common symptom. More than 60 million Americans have ... examine where heartburn starts, and how it can be ...
(Date:3/28/2015)... March 28, 2015 The California-based leading ... for every customer shopping on UniWigs during the Easter ... be a big promotion on April Fools’ Day. , ... is just around the corner. Easter Festival, with religious ... is a major holiday after Christmas. The best wig ...
(Date:3/28/2015)... New York, NY (PRWEB) March 28, 2015 ... 2015 highlighted a problem which could prove critical to ... Why system testing, a critical aspect of data security, ... payment card industry data security report, every major category ... vulnerability scanning and penetration testing. “With all the craziness ...
(Date:3/28/2015)... Las Vegas, NV (PRWEB) March 28, 2015 ... surgery experiences re-injury, according to research presented today at ... ) Specialty Day. The study examined the long term ... younger. , “We examined survey data from 242 ... noted lead author Justin P. Roe, MBBS, FRACS, from ...
Breaking Medicine News(10 mins):Health News:New Research Impliments Coffee May Help Fight Gum Disease and Increasing Benefits With Tylers Coffee 2Health News:Bypass Your Heartburn Worries This Easter With Tylers Coffee 2Health News:UniWigs Is Sending Out Mysterious Gifts During the Easter Holidays 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2
... against infection, study shows , WEDNESDAY, June 17 (HealthDay ... emphysema also defends the lungs against bacterial infection, a ... the only thing macrophage elastase, matrix metalloproteinase-12 (MMP-12), did ... destruction seen in emphysema patients. , "But we found ...
... ... provider customers in discussions about healthcare reform, the importance of Medicare to their business ... healthcare objectives. , ... Stamford, CT (Vocus) June 18, 2009 -- IVANS, Inc. has been regularly ...
... Professional Launches Exclusive Product Solution With Microban Antimicrobial Protection to ... Ga., June 17 If you thought a toilet seat ... again. , , According to new research ... of Arizona , the average toilet paper dispenser has more ...
... LONDON, June 17 MediciGlobal, a leading ... Distinction in The 2009 Communicator Awards from ... Awards is the leading international awards program honouring creative ... won awards on behalf of three global pharmaceutical clients ...
... quality improvement and affordable coverage for all Americans , ... Majority Leaders Howard Baker, Tom Daschle and Bob Dole, ... today released a bipartisan, budget-neutral framework for comprehensive health ... health coverage. The Leaders, Project on the State of ...
... Across North America , , THOUSAND OAKS, Calif., ... today announced the 34 science teachers in the United States (U.S.), ... Amgen Award for Science Teaching Excellence. The award recognizes teachers ... impact on the learning and interest of the future generation of ...
Cached Medicine News:Health News:Lung Enzyme Both Friend and Foe 2Health News:IVANS Hit Experts Available To Discuss the Dept. of HHS Recommendation Of “Meaningful Use” and How Potential Tighter Standards Will Impact the Provider Community 2Health News:IVANS Hit Experts Available To Discuss the Dept. of HHS Recommendation Of “Meaningful Use” and How Potential Tighter Standards Will Impact the Provider Community 3Health News:Research from Dr. Charles Gerba Finds Average Toilet Paper & Towel Dispensers Have More Bacteria Than Average Toilet Seat 2Health News:Research from Dr. Charles Gerba Finds Average Toilet Paper & Towel Dispensers Have More Bacteria Than Average Toilet Seat 3Health News:MediciGlobal Wins Four International 2009 Communications Awards for Patient Recruitment and Retention 2Health News:Former Senate Majority Leaders Baker, Daschle and Dole Release Bipartisan Framework for Comprehensive Health Reform 2Health News:Former Senate Majority Leaders Baker, Daschle and Dole Release Bipartisan Framework for Comprehensive Health Reform 3Health News:Former Senate Majority Leaders Baker, Daschle and Dole Release Bipartisan Framework for Comprehensive Health Reform 4Health News:34 Outstanding Teachers and Schools Receive $10,000 Amgen Award for Science Teaching Excellence 2Health News:34 Outstanding Teachers and Schools Receive $10,000 Amgen Award for Science Teaching Excellence 3Health News:34 Outstanding Teachers and Schools Receive $10,000 Amgen Award for Science Teaching Excellence 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: